Exhibit 99.1






Derek Cole

Vice President, Investor Relations






Westminster, CO, February 27, 2008

— Allos Therapeutics, Inc. (Nasdaq: ALTH) today reported results for its fiscal year ended December 31, 2007 and outlined its key objectives for 2008.  For the year ended December 31, 2007, the Company reported a net loss of $39.4 million, or $0.60 per share, compared to a net loss of $30.2 million, or $0.55 per share, for 2006. For the year, net cash used in operating activities was $30.8 million.  Cash, cash equivalents and investments in marketable securities as of December 31, 2007 totaled $57.8 million.


“During 2007, we executed our strategic plan resulting in significant advancements in the development of PDX in hematologic malignancies and solid tumors,” said Paul L. Berns, President and Chief Executive Officer.  “We also strengthened the Company’s leadership team through the addition of experienced industry veterans to our senior management and Board of Directors. For 2008, we are focused on driving our PDX product development and commercialization plan, including the completion of PROPEL, our FDA SPA-approved pivotal Phase 2 study of PDX in patients with relapsed or refractory peripheral T-cell lymphoma, and planning for the potential commercialization of PDX.”


2007 and Recent Corporate Highlights


PDX (pralatrexate)


·                  Completed pre-specified interim analyses of patient safety and response data from PROPEL.


·                  Results of the interim analyses of patient safety data for the first 10, 35 and 65 evaluable patients supported continuation of the trial per the protocol in accordance with the recommendations of an independent data monitoring committee (DMC).


·                  Results of the interim analysis of patient response data exceeded the pre-specified threshold for continuation of the trial, which required a minimum of four responses (complete or partial) out of the first 35 evaluable patients, as determined by independent oncology review.


·                  Received orphan medicinal product designation for the treatment of patients with PTCL from the Commission of the European Communities.


·                  Favorable opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMEA).


The following information was filed by Allos Therapeutics Inc (ALTH) on Wednesday, February 27, 2008 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Allos Therapeutics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Allos Therapeutics Inc.


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account